The most widely prescribed COPD inhalers fall into three categories: triple therapies that combine three active drugs, dual bronchodilators, and single-agent maintenance inhalers. The five inhalers that come up most in treatment guidelines are Trelegy Ellipta, Breztri Aerosphere, Anoro Ellipta, Spiriva (Respimat or HandiHaler), and Symbicort. Which one is right for you depends on how severe your COPD is, how often you have flare-ups, and how easily you can use the device itself.
Trelegy Ellipta: The Leading Triple Therapy
Trelegy Ellipta is a once-daily dry powder inhaler that delivers three medications in a single puff: a steroid to reduce airway inflammation, plus two different bronchodilators that open the airways through separate mechanisms. It’s typically prescribed for people with moderate to severe COPD who still have frequent flare-ups despite using simpler inhalers.
In a large comparative study published in The BMJ, Trelegy outperformed its closest competitor (Breztri Aerosphere) in preventing exacerbations. Patients on Breztri had a 9% higher rate of moderate or severe flare-ups and a 29% higher rate of severe flare-ups requiring hospitalization compared to those on Trelegy. That translated to roughly one extra hospitalization for every 97 patients treated with Breztri instead of Trelegy over a year. The once-daily dosing is another practical advantage: one inhalation each morning and you’re done.
Breztri Aerosphere: A Triple Therapy Alternative
Breztri Aerosphere contains the same three classes of medication as Trelegy but uses different active compounds and a different device. It’s a pressurized metered-dose inhaler (the classic “press and breathe” type) rather than a dry powder inhaler, and it requires two puffs twice daily instead of one puff once daily.
For some people, Breztri is actually easier to use. Metered-dose inhalers don’t require the quick, deep breath that dry powder inhalers need to work properly. If you have very weak lung function and struggle to inhale forcefully, the Breztri device may deliver medication more reliably. The trade-off is that metered-dose inhalers demand better hand-breath coordination: you need to press the canister and inhale at the same time. A spacer device can help if that timing is difficult. On cost, Breztri currently has a $0 out-of-pocket cap through an AstraZeneca savings program, while Trelegy is capped at $35 per month through GlaxoSmithKline’s program.
Anoro Ellipta: Dual Bronchodilator Without a Steroid
Anoro Ellipta pairs two long-acting bronchodilators in a single once-daily inhaler. It opens the airways through two different pathways but does not contain a steroid. This makes it a strong choice for people whose main issue is daily breathlessness rather than repeated flare-ups, and for those who want to avoid the side effects that come with long-term steroid use.
In FDA registration trials, Anoro improved lung function (measured by how much air you can force out in one second) by about 200 mL from baseline. That was roughly 50 to 110 mL better than either bronchodilator alone, which is a clinically meaningful difference. For context, 200 mL of improvement can be the difference between getting winded walking across a parking lot and handling it comfortably.
Because it skips the steroid component, Anoro avoids the increased pneumonia risk that comes with inhaled corticosteroids. Data from the large TORCH trial found that COPD patients using a steroid-containing inhaler had a 64% higher risk of developing pneumonia over three years compared to placebo. That’s a real consideration if your flare-ups are infrequent and your main goal is better day-to-day breathing. Anoro is dosed once daily, same Ellipta device as Trelegy, and is covered under the $35 cap.
Spiriva: The Gold-Standard Maintenance Bronchodilator
Spiriva contains tiotropium, a single long-acting bronchodilator that relaxes the muscles around your airways for a full 24 hours. It’s one of the most studied COPD medications in existence and is often the first maintenance inhaler prescribed after a short-acting rescue inhaler isn’t enough on its own.
Spiriva comes in two devices. The HandiHaler is a dry powder inhaler that uses individual capsules: you load one capsule, pierce it, and inhale deeply. The Respimat is a soft mist inhaler that turns liquid medication into a slow-moving aerosol cloud. Clinical trials show the two versions produce virtually identical lung function improvements (the difference was just 8 mL, which is negligible). The Respimat has a practical edge for people with weaker lungs because it generates the mist on its own rather than relying on your breath to pull powder from the device. It also requires less coordination than a standard metered-dose inhaler.
Both versions are once-daily (one capsule for HandiHaler, two puffs for Respimat) and both fall under Boehringer Ingelheim’s $35 out-of-pocket cap. Spiriva is less powerful than a dual or triple combination, but its simplicity and long safety track record make it a common starting point.
Symbicort: Steroid Plus Bronchodilator Combination
Symbicort pairs an inhaled corticosteroid with a long-acting bronchodilator in a dry powder Turbuhaler device. It’s dosed at two inhalations twice daily. Symbicort is prescribed for COPD patients who need both inflammation control and airway opening but aren’t yet at the point of needing triple therapy.
The twice-daily schedule is a drawback compared to once-daily options. Because Symbicort contains a steroid, it carries the same pneumonia risk as other steroid-containing inhalers, so it’s best suited for people who have a history of flare-ups where inflammation plays a clear role. One marker your doctor may look at is your blood eosinophil count: higher levels suggest you’re more likely to benefit from the steroid component. Symbicort is covered under AstraZeneca’s $35 cap.
How Inhaler Devices Affect Your Results
The medication inside the inhaler only works if it actually reaches your lungs, and that depends heavily on the device. There are three main types you’ll encounter across these five inhalers:
- Dry powder inhalers (Ellipta, HandiHaler, Turbuhaler): Require a quick, deep breath to pull the powder into your lungs. No hand-breath coordination needed since you just inhale, but they don’t work well if your inspiratory strength is very low.
- Metered-dose inhalers (Breztri Aerosphere): Spray a measured dose when you press the canister. Require a slow, steady breath and good timing between pressing and inhaling. A spacer can help if coordination is tricky.
- Soft mist inhalers (Spiriva Respimat): Generate a slow-moving mist that doesn’t depend on your breathing strength. Easiest to use for people with weak lungs and require less coordination than the other two types.
Getting the wrong device can mean most of your medication ends up in your mouth and throat instead of your airways. If you find yourself not improving on a medication that should be working, the device itself may be the problem.
What You’ll Actually Pay
All five of these inhalers are brand-name medications, but manufacturer savings programs have changed the cost picture significantly. Following a 2024 U.S. Senate investigation, GlaxoSmithKline (Trelegy, Anoro), Boehringer Ingelheim (Spiriva), and AstraZeneca (Breztri, Symbicort) all introduced out-of-pocket caps. Trelegy, Anoro, Spiriva, and Symbicort are capped at $35 per 30-day supply. Breztri is capped at $0.
For people with employer-sponsored insurance, the median out-of-pocket cost for a brand-name inhaler was $25 per fill in 2023, though about a third of fills still exceeded $35. The savings caps apply regardless of your insurance tier, but eligibility details vary, so check each manufacturer’s program directly. If you’re on Medicare, these caps may not apply, though the Inflation Reduction Act’s $2,000 annual out-of-pocket limit on Part D drugs provides a separate ceiling.